Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration ("FDA"), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration ("FDA") for Aldara® 5% imiquimod cream to treat actinic keratosis are also disclosed and described.揭示及說明用於局部或經皮輸送1-異丁基-1H-咪唑并[4,5-c]-喹啉-4-胺或1-(2-甲基丙基)-1H-咪唑并[4,5-c]-喹啉-4-胺，亦即咪喹莫特之醫藥調配物及方法，該醫藥調配物及方法係用於治療光化性角化病，其與目前被處方且已獲得美國食品藥物管理局(FDA)許可之市售樂得美(Aldara®)5%咪喹莫特乳膏劑相較，具有較短的治療期。更特定而言，揭示及說明較低劑量強度咪喹莫特調配物，其可輸送治療光化性角化病之有效劑量之咪喹莫特，且具有可接受的安全性，而且與目前美國食品藥物管理局(FDA)所許可之樂得美(Aldara®)5%咪喹莫特乳膏劑之給藥療程相較，可提供較短期且便於病人使用之給藥療程。
